Development of an fviii inhibitor in a mild hemophilia patient with a phe595cys mutation

1Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Mild hemophilia A is caused by a missense mutation in the FVIII gene that is responsible for a decrease in the FVIII:C to between 5% and 40%. The development of FVIII inhibitors has been reported in 3-13% of patients with mild hemophilia. Genetic risk factors for the development of inhibitors in mild hemophilia have been investigated. In the present study, we encountered a case of mild hemophilia with an FVIII inhibitor and identified the mutation responsible: a novel Phe595Cys mutation in the FVIII gene. In addition, this study showed that the inhibitor recognized exogenous wild-type FVIII and autologous mutant FVIII.

Cite

CITATION STYLE

APA

Yamanouchi, J., Tokumoto, D., Ikeda, Y., Maruta, M., Kaneko, M., Hato, T., & Yasukawa, M. (2018). Development of an fviii inhibitor in a mild hemophilia patient with a phe595cys mutation. Internal Medicine, 57(21), 3179–3182. https://doi.org/10.2169/internalmedicine.1145-18

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free